Insider Trading Pulse — July 02, 2026

CEO Escorsa Enric Asuncion bought 325,885 shares ($887K) and Director Richer Marc Sabe bought 501,361 shares ($1.36M) on the same day, representing a combined $2.25M in insider buying. This is the highest-conviction insider purchase signal in the digest, especially with no insider selling elsewhere

10% owner Uber Technologies, Inc. purchased 800,000 shares for $20M at $25/share, a massive vote of confidence. This is the largest single insider transaction by value today and shows a strategic backer doubling down on a private-mobility investment

Director De Soto Matthew G bought 287 shares (~$10K) in the open market, a rare cash purchase among a sea of grants. With post-transaction holdings of 119,130 shares, this signals director conviction at current levels

10% owner Horizon Kinetics bought 1 share for $426, a symbolic purchase that maintains a perfect zero-selling record. While immaterial in size, the consistency of no insider selling at all-time highs is a bullish signal

CFO Bueker Kathryn had 781 shares withheld for taxes ($147K) at $187.72, with no open-market selling. The CFO retains 56,349 shares, indicating no loss of confidence despite the tax obligation [NEUTRAL/BULLISH]

COO Gryzlov Yury had 1,686 shares withheld for taxes ($10.5K) at $6.24, a minor disposal. With 513,262 shares retained, the COO maintains heavy skin in the game

Executive Chairman Moradi David had 3,804 shares withheld for taxes ($22K) at $5.81, but retains 803,301 shares. The executive chairman's massive holding indicates strong alignment with shareholders [NEUTRAL/BULLISH]

Director Phyllis Yale received 607 DSUs at $57.62, a routine director compensation grant. The lack of any insider selling at a mega-cap biotech is a mildly positive signal

Director Edward Rapp received 134 stock equivalent units at $251.64 ($33.7K). Consistent with BMS, no insider selling across large-cap pharma is notable

Two directors received share equivalent units totaling $106K at $334.04, indicating ongoing board retention without any insider selling

Four directors were awarded a combined 119,429 shares in stock grants, totaling significant director-level compensation. This signals the board is being incentivized with equity at a key stage for the biotech [NEUTRAL/BULLISH]

Three directors received 125,000 stock options each (375,000 total), a material option grant for a pre-commercial biotech. This links director compensation to share price appreciation, a bullish long-term signal

Three directors received phantom stock units (180, 433, and 159 units) via automatic dividend reinvestment. While routine, the use of phantom shares rather than real equity could indicate a desire to avoid direct insider ownership signaling

Director Sundaram Easwaran received fractional shares (90.467) at $345.43 (~$31K) and Director Wajsgras received identical awards, representing automatic dividend reinvestment. The high stock price ($345) and small grant sizes suggest no active conviction signal

CEO DePasquale Michael W was awarded only 250 shares at $3.83 (~$958), a tiny grant relative to a CEO's typical stake. The small award size might indicate limited board confidence or a cash conservation strategy

Director Todd Ware received only 21 shares of Class C non-voting stock at $199.27 (~$4.2K), the smallest director grant in the digest by share count. The non-voting class limits director alignment

Director Bernd Kessler received 531 shares at $64.73 (~$34K), which is below the average director grant size for large-caps. With the stock trading at $64.73, the grant value is modest

Director Michael Mears received 136.81 phantom shares at $91.37 (~$12.5K), a small award for a utility giant. The use of phantom shares rather than actual stock reduces insider ownership signaling

Director Jeffrey Shaw received 564 shares at $77.63 (~$43.8K), a routine grant. The utility sector generally sees low insider turnover, so this is no red flag but offers no bullish signal

Director Jeffrey Honickman received 1,783 shares and now holds 271,783 shares, a substantial holding. No open-market purchases or sales from this large holder is neutral, but the lack of buying at current levels is notable

Director Steven Chaouki received 26,982 stock options, a significant grant for a small biotech. While grants are common, the option-heavy comp structure can lead to risk-taking behavior

Director Abhay Pande exercised/converted 135 restricted stock units into common stock, a small conversion that suggests the stock is trading at levels that make exercise worthwhile. No cash sale indicates retention

CEO and director combined for $2.25M in open-market purchases at an average price of $2.72. With two insiders buying aggressively on the same day, this signals expectations of a significant inflection point for the EV charging company. The CEO now holds 1.2M shares and the director holds 1.5M shares

Uber's $20M open-market purchase at $25/share is a rare instance of a 10% owner making a deliberate, large-scale increase in a publicly-traded holding company. This suggests Uber sees significant upside in Lime's micro-mobility business, potentially ahead of an IPO or strategic transaction

Director De Soto bought shares in the open market at $34.84, a rare cash purchase amid a digest full of awards. Regional banks are under pressure from rate uncertainty, but insider buying at this level signals local management confidence in credit quality and earnings

Three directors received 125,000 stock options each, with no strike price disclosed. For a pre-commercial biotech, option grants tie board compensation entirely to stock price appreciation—a strong alignment mechanism ahead of potential catalysts

Four directors received a combined 119,429 shares of common stock in what appears to be a one-time or annual grant event. For a development-stage biotech, this level of director stock ownership provides significant alignment with shareholders ahead of clinical data readouts

Executive Chairman Moradi retains 803,301 shares after a minor tax withholding. At $5.81, the stock appears undervalued for a company with growing digital accessibility demand. The massive insider holding creates a natural incentive for value realization

COO retains 513,262 shares after a negligible tax sale at $6.24. For an IT services company, this level of insider ownership in a depressed stock price environment could signal a pending value unlock

10% owner Horizon Kinetics bought 1 share to maintain their position, but the key opportunity is the total absence of insider selling. At all-time highs, insiders are choosing not to sell—a rare signal of confidence in a stock up significantly

Director Sameer Gandhi received 22,698 shares, a large grant for a SaaS company. As a venture-back director at a high-growth SaaS firm, this grant signals ongoing board commitment and potential for product-led growth resurgence

Director David Obstler received 7,753 Class A shares, maintaining 75,805 shares. For a high-growth customer engagement platform, insider holdings of this size suggest management sees the current valuation as a long-term opportunity

4 biotech companies (Lineage Cell Therapeutics, Dare Bioscience, MAIA Biotechnology, and TIC Solutions) saw director grants totaling over 500,000 options and shares. This pattern indicates that pre-commercial biotechs are aggressively incentivizing boards with equity to drive value creation ahead of clinical milestones

44 of 50 filings (88%) were director compensation grants, restricted stock awards, or deferred share units—not open-market trades. This is a typical pattern for a single day, but it means the real trading signal is found in the 6 open-market purchases (Wallbox, Neutron, Mid Penn, Texas Pacific Land, and AudioEye tax sale)

Companies like American Express, Bristol Myers, AbbVie, Comcast, and Prologis showed only automatic dividend reinvestments or director grants. The absence of insider buying at mega-caps suggests insiders see better value in smaller names or are waiting for clearer macro signals

Only 3 filings involved tax-withholding dispositions (HubSpot, AudioEye, Grid Dynamics), totaling ~$180K. The near-total absence of insider selling—even for tax purposes—is a strongly bullish cross-sector signal for the digestion period

The most significant open-market buying ($22.5M combined) was concentrated in Wallbox (EV charging) and Neutron Holdings (micro-mobility). This suggests insiders see outsized opportunity in specialized growth companies at depressed valuations, versus broad market indices

13 filings came from tech companies (HubSpot, AudioEye, Cloudflare, Braze, Freshworks, Grid Dynamics, etc.), yet none involved open-market purchases. The absence of tech insider buying despite recent sector weakness is a notable divergence from the small-cap buying seen elsewhere

Watch for additional insider filings following the $2.25M purchase by CEO and director. Any further buying at current levels would confirm the bullish thesis. Next earnings call likely in August 2026 to discuss EV charging demand trends

Monitor for any SEC filings around potential IPO or strategic investment. Uber's $20M purchase at $25/share could precede a larger capital markets event. Watch for Form 13D amendments from Uber

Watch for additional director buying activity. Regional bank earnings season could provide a catalyst if credit quality holds. Director De Soto's purchase at $34.84 establishes a personal cost basis

Monitor for clinical trial catalysts. The director option grants (375,000 total) are a strong alignment signal—any positive data readout could drive significant upside for this pre-revenue biotech

Watch for upcoming FDA decisions or partnership announcements. The large director stock grants (119,429 shares combined) suggest the board expects value realization in the near term

Monitor CFO withholding for taxes—any open-market selling following this minor tax event would be a bearish signal. HubSpot is a bellwether for SaaS spending trends

Watch for any Form 4 filings showing executive Chairman Moradi selling shares. His 803,301-share holding is a massive concentration—any reduction would be a strong negative signal

Monitor for additional insider transactions or corporate events. With COO retaining 513K shares at $6.24, any insider buying at these levels would be a powerful bullish signal

Watch for any insider open-market selling. The complete absence of insider sales at mega-cap pharma is notable—any unexpected selling would be a risk signal for the sector